Hugh Goodfellow
Partner

Hugh leads the Life Sciences team at Carpmaels & Ransford. As part of his role, he spends much of his time overseeing teams of attorneys who assist innovator companies in protecting their commercial products. Accordingly, he has a large prosecution practice and is a regular visitor to the European Patent Office (EPO), handling many oppositions and appeals. With so many projects running in parallel between the EPO and national litigation, he also forms a cornerstone of Carpmaels and Ransford’s dispute resolution practice, acting as a strategic link between these two coordinated systems. He has extensive experience of patent prosecution in countries outside Europe and has pan-European expertise in the filing and prosecution of supplementary protection certificates nationally, as well as considerable experience and success before the European Court of Justice, including the widely cited Queensland (C-630/10) and Neurim (C-130/11) referrals. 

Hugh has an “expansive practice” (IAM Patent 1000) with clients ranging from large and long-established global companies (e.g. Janssen Biotech, Janssen Sciences, Shire, Gilead, Celgene, Regeneron and Vertex) through to European biotech companies (eg, Akari, Hubrecht Institute, Gene Bridges and Tigenix). During his career, he has been responsible for establishing the filing strategy and generating IP portfolios for a number of start-ups, guiding some of these clients all the way from early conception, through financing rounds and subsequent public flotation. His particular area of current focus includes biologics – in particular, therapeutic antibodies, complex immunology, biosimilars and stem cells. Collectively, these experiences have developed Hugh’s ability to consistently and successfully protect foundation intellectual property and forecast potential future problems from the viewpoint of both IP generation and freedom to operate. Hugh has been noted as a “top-tier advisor” who “seamlessly links the firm’s prosecution division with its dispute resolution arm” (IAM Patent 1000).

Hugh received his BA (Hons) in biochemistry and his MA and DPhil from the University of Oxford. His experience at the bench was spent investigating mechanisms of drug resistance in cancer cells.

Hugh Goodfellow is a "very client-friendly" patent attorney with a focus on life sciences. He advises on domestic and European patent filing strategies and also assists with due diligence with regard to corporate deals.
Chambers & Partners, 2018
Qualifications
  • BA (Hons) and MA Biochemistry (University of Oxford)
  • DPhil (University of Oxford)
  • Chartered Patent Attorney
  • European Patent Attorney